Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia.

Kishi T, Suzuki T, Sekiguchi H, Moriwaki M, Okuda A, Mekata T, Hattori M, Tsunoka T, Chekuri R, Musso GM, Fujita K, Iwata N.

Asian J Psychiatr. 2013 Feb;6(1):86-7. doi: 10.1016/j.ajp.2012.08.006. Epub 2012 Sep 30. No abstract available.

PMID:
23380329
2.

A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.

Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG.

J Clin Psychiatry. 2008 Feb;69(2):274-85.

PMID:
18232726
3.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
4.

[Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].

Meder J, Debowska G, Lis J, Araszkiewicz A, Sierosławska K, Kolesaric A, Treuer T.

Psychiatr Pol. 2004 May-Jun;38(3):469-84. Polish.

PMID:
15199656
6.

High-dose olanzapine for treatment-resistant schizophrenia.

Roth BL.

J Clin Psychiatry. 2008 Feb;69(2):176-7. No abstract available.

PMID:
18363451
7.

Re: treatment noncompliance with orally disintegrating olanzapine tablets.

Citrome L.

Can J Psychiatry. 2004 Jun;49(6):412-3; author reply 413. No abstract available.

PMID:
15283540
8.

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.

Hill AL, Sun B, Karagianis JL, Watson SB, McDonnell DP.

BMC Psychiatry. 2011 Feb 15;11:28. doi: 10.1186/1471-244X-11-28.

9.

Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia.

Suarez D, Haro JM, Novick D, Perrin E, Ochoa S, Naber D.

Pharmacopsychiatry. 2009 Jul;42(4):135-40. doi: 10.1055/s-0028-1112127. Epub 2009 Jul 7.

PMID:
19585391
10.

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.

Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson DR, Citrome L.

J Clin Psychopharmacol. 2008 Aug;28(4):392-400. doi: 10.1097/JCP.0b013e31817e63a5.

PMID:
18626265
11.

Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.

Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J.

J Clin Psychopharmacol. 2008 Dec;28(6):601-7. doi: 10.1097/JCP.0b013e31818aaf6c.

PMID:
19011427
12.

Adolescent with treatment-refractory schizophrenia and clozapine-induced cardiomyopathy managed with high-dose olanzapine.

Bobb VT, Jarskog LF, Coffey BJ.

J Child Adolesc Psychopharmacol. 2010 Dec;20(6):539-43. doi: 10.1089/cap.2010.2062. No abstract available.

PMID:
21186975
13.

Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.

Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I, Chouinard G, Morris PL, Breier A.

Can J Psychiatry. 2003 Dec;48(11):716-21.

PMID:
14733451
14.

Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.

Lambert M, Holzbach R, Moritz S, Postel N, Krausz M, Naber D.

Int Clin Psychopharmacol. 2003 Sep;18(5):251-60.

PMID:
12920385
15.

Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia.

Caforio G, Di Giorgio A, Rampino A, Rizzo M, Romano R, Taurisano P, Fazio L, De Simeis G, Ursini G, Blasi G, Nardini M, Mancini M, Bertolino A.

J Clin Psychopharmacol. 2013 Dec;33(6):810-2. doi: 10.1097/JCP.0b013e3182a4ec77. No abstract available.

PMID:
24113675
16.

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.

Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H.

Psychopharmacology (Berl). 2007 Dec;195(2):285-95. Epub 2007 Aug 14.

PMID:
17701027
17.

Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.

Bhowmick S, Hazra A, Ghosh M.

Aust N Z J Psychiatry. 2010 Mar;44(3):237-42. doi: 10.3109/00048670903487134.

PMID:
20050717
18.

The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study.

Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr.

J Clin Psychopharmacol. 2003 Dec;23(6):668-71. No abstract available.

PMID:
14624201
19.

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.

Witte MM, Case MG, Schuh KJ, Ascher-Svanum H.

Curr Med Res Opin. 2012 Mar;28(3):315-23. doi: 10.1185/03007995.2012.657300. Epub 2012 Jan 31.

PMID:
22236137
20.

Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.

Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S.

J Clin Psychiatry. 2004 Nov;65(11):1525-30.

PMID:
15554767
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk